Similar articles

• Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.

  Petersen SL. Petersen SL. Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
• Antithymocyte globulin in reduced-intensity conditioning allografting: is the benefit simply in the eyes of the transplanter?

  Hamadani M. Hamadani M. Biol Blood Marrow Transplant. 2014 Mar;20(3):292-4. doi: 10.1016/j.bbmt.2013.12.571. Epub 2014 Jan 3. Biol Blood Marrow Transplant. 2014. PMID: 24394802 No abstract available.
• Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.

  Gürman G, Arat M, Ilhan O, Konuk N, Beksaç M, Celebi H, Ozcan M, Arslan O, Ustün C, Akan H, Uysal A, Koç H. Gürman G, et al. Cytotherapy. 2001;3(4):253-60. doi: 10.1080/146532401317070880. Cytotherapy. 2001. PMID: 12171713 Clinical Trial.
• Comparison of reduced intensity and myeloablative conditioning regimens for stem cell transplantation in patients with malignancies: a meta-analysis.

  Shi-Xia X, Hai-Qin X, Xian-Hua T, Bo F, Xiang-Feng T. Shi-Xia X, et al. Clin Transplant. 2011 Mar-Apr;25(2):E187-98. doi: 10.1111/j.1399-0012.2010.01361.x. Epub 2010 Nov 23. Clin Transplant. 2011. PMID: 21092011
• Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.

  Resnick IB, Shapira MY, Slavin S. Resnick IB, et al. Transpl Immunol. 2005 Aug;14(3-4):207-19. doi: 10.1016/j.trim.2005.03.009. Epub 2005 Apr 26. Transpl Immunol. 2005. PMID: 15982565 Review.